Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16178801 | 0.84 | RYR2 (0.52) | CHRM3SMN1; SMN2OPRK1POLB | |
| SCHEMBL16178785 | 0.80 | EPHX2 (0.62) | SMN1; SMN2ALDH1A1HPGDPOLBMAPK1 | |
| SCHEMBL5470035 | 0.79 | MEN1 (0.61) | SMN1; SMN2ALDH1A1HPGDOPRK1LMNA | |
| SCHEMBL16178769 | 0.79 | NPC1 (0.57) | SMN1; SMN2ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL4557723 | 0.77 | RAB9A (0.55) | CHRM3SMN1; SMN2ALDH1A1HPGDLMNA | |
| SCHEMBL14941502 | 0.77 | EPHX2 (0.47) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL16178752 | 0.77 | MLNR (0.48) | CHRM3ALDH1A1 | |
| SCHEMBL4991673 | 0.72 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1HPGDLMNAHSD17B10 | |
| SCHEMBL179085 | 0.72 | RAB9A (0.76) | SMN1; SMN2ALDH1A1HPGDLMNAHSD17B10 | |
| SCHEMBL8921461 | 0.71 | HTT (0.77) | ALDH1A1LMNAPOLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | CHRM3 4181/4885SMN1; SMN2 3142/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.